Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 1085-1089

  Woodis, C Brock ^a,b  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Postmenopausal osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DENSITY; BONE NECROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; EMBASE; FEMUR NECK; FEVER; HEADACHE; HIP; HUMAN; JAW DISEASE; LUMBAR SPINE; MEDLINE; MYALGIA; OSTEOLYSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 48249113953     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K652     Document Type: Review

References (17)

1. Bone health and osteoporosis: a report of the Surgeon General. US Public Health Services. Department of Health and Human Services, www.surgeongeneral. gov/library/bonehealth/docs/Chapter_4.pdf (accessed 2008 Feb 18).
2. Anderson SJ. Osteoporosis in the older woman. Clin Obstet Gynecol 2007;50:752-66.
3. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28:151-73.
4. Rosen CJ. Cinical Pactice. Postmenopausal osteoporosis. N Engl J Med 2005;353:595-603.
5. Osteoporosis ACOG practice bulletin. Obset Gynecol 2004;103:203-16.
6. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006;119(4 suppl 1): S25-31. DOI 10.1016/j.amjmed.2005.12.020
7. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46.
8. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65.
9. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60. DOI 10.1185/030079905X61875
10. Package insert. Reclast (zoledronic acid). East Hanover, NJ: Novartis Pharmaceuticals Corp., August 2007.
11. Reid IR, Brown JP, Burkhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
12. Saag K, Lindsay R, Kriegman A, Beamer E, Wenchun Z. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40:1238-43. DOI 10.1016/j.bone.2007.01.016
13. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41:122-8. DOI 10.1016/j.bone.2007.03.011
14. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
15. Devogelaer JP, Brown JP, Burkhardt P, et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 2007;18:1211-8. DOI 10.1007/s00198-007-0367-3
16. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical features and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
17. Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548-58.